The Chinese pharmaceutical R&D chemistry product and service provider PharmaBlock Sciences has reportedly announced to have purchased a GMP-compliant manufacturing plant in Shangyu, China. As per trusted sources, the facility has been acquired from Porton Pharma Solutions.
Located in a state-level chemical industry park in Zhejiang Province, the site spreads over 1,436,000 square feet of land and has been operating a GMP-compliant multi-purpose facility since December 2015. Reportedly, the facility has been equipped with 300 L to 6300 L and more than 180 m3 of combined reactor volume that practice a wide range of enabling technologies and chemistry synthesis.
Chairman of PharmaBlock Sciences, Dr Minmin Yang, was reportedly quoted stating that the new site of the firm at Shangyu is well-positioned to fulfil the growing customer demand for commercial-, clinical-, and preclinical-stage manufacturing of intermediates. The Phase II construction of the Shangyu facility would be initiated in late 2018 to establish API manufacturing capacities.
Moreover, the latest acquisition has supplemented the existing assets of the Shandong Dezhou facility and has provided an additional GMP capability, Yang added. Sources familiar with the development claim that the company would soon be able to provide its consumers with an integrated supply chain ranging from non-GMP intermediates, building blocks, GMP intermediates to APIs.
In the past two years, the company has implemented enabling technologies including fluorination, electro synthesis, photochemistry, bio catalysis, and flow chemistry. Additionally, PharmaBlock purchased Shangdong Diai Biotechnology in 2016 as its first pilot plant and manufacturing site, cite trusted sources.
For the record, the company appointed Dr Shijie Zhang as the new Chief Technology Officer in early September. According to a statement of PharmaBlock, the addition of Zhang to the team would strengthen its contract development, manufacturing organization business, competence in process development, and enhance its overall team. Moreover, the firm boosted its footprint in the U.S. by renovating its new Process R&D Center near Philadelphia.